To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open1,540
High1,540
Low1,540
Prev. Close1,559.4
Avg. Traded Price1,540
Volume12,769

MARKET DEPTH

info2
Total bid14,686.00
Total ask19,885.00
OrdersQtyBid
152971540
16501539.5
214081538
111535.1
4381535
AskQtyOrders
1542160
1544160
1545149
1546160
1548285

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

0.00
0.00
arrow

LOWER/UPPER CIRCUITS

1,403.50
1,715.30
arrow
Cipla Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 7.12%, in the last year to ₹28,409.49 Cr. Its sector's average revenue growth for the last fiscal year was 10.77%.
noteAnnual Net Profit,rose 27.93% in the last year to ₹5,272.52 Cr. Its sector's average net profit growth for the last fiscal year was 38.71%.
notePrice to Earning Ratio,is 23.36, lower than its sector PE ratio of 44.81.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 23.13%
Net profit growth 5Y CAGR : 22.45%

STOCK RETURNS

info
Versus Nifty 50
1 w
+7.35%
vs
-1.52%
1 mth
+4.39%
vs
-3.28%
3 mth
+1.98%
vs
+1.42%
6 mth
+10.40%
vs
+6.55%
1 yr
+1.16%
vs
-0.62%
3 yr
+60.83%
vs
+43.84%
5 yr
+130.75%
vs
+120.31%
Cipla Ltd Top mutual funds holding
arrow
Cipla Limited, established in 1935, is a global pharmaceutical company with a strong commitment to make medicines accessible and affordable to those in need. The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Its product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS and various other key therapeutic segments. With a rich portfolio, the company is deepening its presence in the home markets of India, as well as South Africa, North America and other key regulated and emerging markets.
personal

Grow your wealth with more research recommendations

+91